S22 Is primary chemotherapy useful in all patients?

Scholl, S.; Beuzeboc, Philippe; Asselain, Bernard; Pierga, Jean Yves; Pouillart, P

doi:10.1016/s0959-8049(97)89196-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a trend towards a better outcome in patients whose tumors showed a complete pathological response. [3][4][5] In order to obtain better efficacy of this regimen, the dose of TNCF drugs could be increased. However, since the limiting factor of TNCF treatment is the hematological toxicity, PBPC support would be required.…”

Section: Discussionmentioning

confidence: 99%

Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer

Charrier

Chassagne

Curé

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:In order to evaluate the mobilization of peripheral blood progenitor cells (PBPC) after an effective induction regimen in breast cancer, we performed a study on 15 breast cancer patients. Between January 1995 and June 1996, these patients received TNCF (THP-doxorubicin, vinorelbine, cyclophosphamide, fluorouracil for four days, every 21 days) with G-CSF support (5 g/kg for 10 days after chemotherapy) to reduce aplasia. This regimen is known to result in a complete pathological response in 30% of patients. Between two cycles of TNCF treatment, hematological recovery was observed. Progenitor cells (CFU-GM and CD34 ؉ cells) and mononuclear cells in DNA synthesis (MCDS) counts were performed daily, between the 12th and 17th postchemotherapy days (81 samples). The results showed a similarity for hematological recovery and PBPC mobilization kinetics depending on the number of treatment cycles. The three methods used for PBPC evaluation were well correlated (P Ͻ 0.01) with an optimal mean PBPC recruitment by the last day of G-CSF administration: respectively, 11 520 (1729-26 539) CFU-GM/ml of blood, 249 (14-1160) CD34 ؉ cells/ l of blood and 211 (21-554) MCDS/ l of blood. These results suggested that a daily injection of G-CSF after one or two TNCF cycles will produce an effective PBPC mobilization in comparison with currently used regimens.

show abstract

Section: Discussionmentioning

confidence: 99%